Prosecution Insights
Last updated: November 04, 2026
Application No. 18/702,695

MUCOSAL VACCINE, METHODS OF USE AND ADMINISTRATION THEREOF

Non-Final OA §103§112
Filed
Apr 18, 2024
Priority
Oct 18, 2021 — provisional 63/262,661 +1 more
Examiner
CHEN, STACY BROWN
Art Unit
1672
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Jiangsu Recbio Technology Co. Ltd.
OA Round
1 (Non-Final)
66%
Grant Probability
Favorable
1-2
OA Rounds
6m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
626 granted / 946 resolved
+6.2% vs TC avg
Strong +40% interview lift
Without
With
+40.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
66 currently pending
Career history
995
Total Applications
across all art units

Statute-Specific Performance

§101
5.8%
-34.2% vs TC avg
§103
30.3%
-9.7% vs TC avg
§102
14.4%
-25.6% vs TC avg
§112
32.1%
-7.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 946 resolved cases

Office Action

§103 §112
DETAILED ACTION Election/Restrictions Applicant’s election of species, filed September 28, 2026, is acknowledged and entered. Claims 23-36 are under examination. The elected species is a boosting composition comprising RSV antigen alone. Specification The disclosure is objected to because of the following informalities: In paragraphs [0019] and [0020] of the specification, “NTV8385” should be “NTC8385”. Appropriate correction is required. Claims Summary Claims 23-33 and 37 Claim 23 is directed to a method for treating or preventing symptoms of a respiratory and/or mucosally transmitted pathogen infection, RSV, in a subject, comprising: Administering, non-mucosally (e.g., intramuscular, among others (claim 29)), to the subject an effective amount of a priming composition comprising a nucleic acid based-expression system encoding an RSV prefusion-F (pre-F) protein; the system comprises a DNA vector or an mRNA molecule (claim 24); the coding sequence of the protein comprises SEQ ID NO: 1 (1725-nt) (claim 25); and Administering, mucosally (e.g., intranasal or inhalation (claim 30)), to the subject an effective amount of a boosting composition comprising the pre-F protein; the pre-F protein comprises SEQ ID NO: 5 (571-aa representing full-length RSV A2 strain pre-F DS-Cav1, humanized) (claim 25), or SEQ ID NO: 6 (513-aa, representing a truncated RSV pre-F) (claim 27); the boosting composition is an aerosolized or sprayed formulation (claim 31); the boosting composition is administered about 1-12 weeks after the priming administration (claim 32); the boosting composition is administered multiple times with an interval of about 2 weeks to 2 months (claim 33). The nucleic acid based-expression system comprises SEQ ID NO: 4 (4726-nt representing NTC8385-VA1-RSV-F-A2, DS-Cav1) (claim 26). SEQ ID NO: 4 contains SEQ ID NO: 1. The adjuvant comprises a CpG ODN, or a CpG ODN and MPL (claim 28). The weight ratio of the nucleic acid based-expression system of the prime composition and the protein antigen of the boost composition is 50:15 (claim 37). Claims 34 and 38 Claim 34 is directed to a method for treating or preventing symptoms of an RSV infection in a subject comprising: Administering to the subject an effective amount of a priming composition comprising a polynucleotide expression vector encoding an RSV pre-F antigen under the control of a promoter; administration is intramuscular, subcutaneous or intradermal; and Administering to the subject an effective amount of a boosting composition comprising one or more aerosolized/sprayed formulations comprising the RSV pre-F antigen alone, and one or more adjuvants, wherein the adjuvant comprises a CpG ODN, or a CpG ODN and MPL; administration is intranasal. The weight ratio of the polynucleotide vector in the prime composition to the protein antigen of the boost composition is 50:15. Claims 35, 36 and 39 Claim 35 is directed to a vaccine kit comprising: a priming composition comprising a polynucleotide vector comprising a polynucleotide vector encoding an RSV prefusion-F (pre-F) protein, formulated for intramuscular, subcutaneous or intradermal administration; and a boosting composition comprising the pre-F protein, formulated for intranasal administration, specifically aerosolized, sprayed or nasal drop (claim 36). The weight ratio of the polynucleotide vector in the prime composition to the protein antigen of the boost composition is 50:15. Claim Objections Claims 34, 35, 36, 38 and 39 are objected to because of the following informality: Claims 34 and 35 misspell the term “intradermally”. Claims 36, 38 and 39 are included in this objection because they are dependent on claims 34 and 35, respectively. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 28-30, 32 and 33 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claims 28-30, 32 and 33, the phrases "such as" and “preferably” render the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 23-34, 37 and 38 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method for preventing symptoms of RSV in a subject, does not reasonably provide enablement for a method of treating symptoms of RSV in a subject. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. The breadth of the claims encompasses the treatment of a subject already experiencing symptoms due to RSV infection. Treatment encompasses alleviation or abrogation of disease symptoms (see paragraph [0065] of the published application US 2024/0415949 A1). The nature of the invention with regard to treatment is that an infected and diseased individual that receives the priming and boosting composition as claimed will experience an improvement in their disease symptoms. The specification is directed primarily to protection against disease, both in the text of the disclosure and the examples. There are no examples of treatment nor any discussion of how treatment is effected for symptomatic individuals. The state of the art with regard to treatment of RSV is either antiviral drugs or managing symptoms (see CDC, Symptoms and Care of RSV, February 20, 2026, website: www.cdc.gov/rsv/symptoms/index.html, accessed October 27, 2026, 2 pages, and abstract of Lea Eiland, J Pediatr Pharmacol Ther, 2009, 14(2):75-85). Vaccines comprising prefusion F protein or mRNA coding for prefusion F protein for RSV are not indicated for treatment (see CDC, RSV Vaccine Guidance for Adults, February 24, 2026, website: www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html, accessed October 27, 2026, 5 pages). Given the breadth of the claims, the nature of the invention, the state of the art, the limited guidance and lack of working examples, and the low level of predictability, it would require undue experimentation to use the method as claimed for treatment. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 35 and 36 are rejected under 35 U.S.C. 103 as being unpatentable over Kwong et al. (US 2016/0046675, “Kwong”). The claims are summarized above. Kwong discloses a prime-boost vaccination method comprising administration of a priming composition that is a DNA-based vaccine or other nucleic acid molecule or vector for gene delivery, and a boosting composition comprising a protein subunit or protein nanoparticle based vaccine (see paragraphs [0012] and [0226]). The antigen is a prefusion F protein of RSV (see paragraph [0005]). Administration is local or systemic (see paragraph [0138]). Administration modes include transdermal, intramuscular, intranasal, subcutaneous, with injectable fluids, intrapulmonary spray or application to a mucosal surface (see paragraphs [0225], [0503], [0520], [0558]). OMP adjuvants in combination with proteins are disclosed for intranasal administration (see paragraph [0520]). Kwong discloses kits comprising the compositions (see paragraphs [0569]-[0570]). While Kwong does not specifically suggest that the polynucleotide vector be formulated for IM, SC or ID administration, it would have been obvious to have selected from any of suggested modes which would have resulted in a liquid or solid that would have been suitable for the broadly claimed “formulated for intramuscular or subcutaneous or intradermal” administration, with a reasonable expectation of success. Similarly, while Kwong does not specifically suggest that the protein antigen be formulated for intranasal administration as an aerosol, spray or nasal drop, it would have been obvious to have selected from any of the suggested modes which would have resulted in, for example, a liquid (suitable for nasal drop), or spray (intrapulmonary spray, see Kwong [0558]), with a reasonable expectation of success. Therefore, the claimed embodiments would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention. Conclusion No claim is allowed. SEQ ID NO: 1, 4 and 5 are free of the prior art of record. Claim 39 is objected to but would otherwise be allowable if rewritten in independent form. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stacy B. Chen whose telephone number is 571-272-0896. The examiner can normally be reached on M-F (7:00-4:30). If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Thomas Visone, can be reached on 571-270-0684. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. /STACY B CHEN/Primary Examiner, Art Unit 1672
Read full office action

Prosecution Timeline

Apr 18, 2024
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779035
TRANSPLANTED CELL PROTECTION VIA INHIBITION OF POLYMORPHONUCLEAR CELLS
4y 3m to grant Granted Nov 03, 2026
Patent 12760316
IgG VARIANTS FOR INDUCTION OF IMMUNE RESPONSE WITHOUT ADJUVANT
4y 1m to grant Granted Oct 13, 2026
Patent 12751617
LYME RELATED INFECTION INDICATOR
3y 5m to grant Granted Oct 06, 2026
Patent 12699093
BIOSENSOR AND METHOD FOR DETERMINATION OF VIRUSES IN CORONAVIRUS FAMILY
3y 1m to grant Granted Aug 04, 2026
Patent 12653883
ALPHAVIRUS NEOANTIGEN VECTORS AND INTERFERON INHIBITORS
5y 1m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
66%
Grant Probability
99%
With Interview (+40.3%)
3y 1m (~6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 946 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month